Effects of Oral Sildenafil on Mortality in Adults With PAH

  • STATUS
    Not Recruiting
  • End date
    Jun 30, 2023
  • participants needed
    429
  • sponsor
    Pfizer
Updated on 4 April 2021
Investigator
Pfizer CT.gov Call Center
Primary Contact
Prince of Wales Hospital (0.0 mi away) Contact
+99 other location
hypertension
connective tissue disease
ventricular septal defect
sildenafil
right heart catheterization
septal defect

Summary

This is a blinded study in adult patients with PAH evaluating the relative effects of sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all three times per day [TID]). In addition, the relative effects on clinical worsening and 6-minute walking distance (6MWD) will be assessed.

Details
Condition Pulmonary Arterial Hypertension
Treatment Sildenafil Citrate
Clinical Study IdentifierNCT02060487
SponsorPfizer
Last Modified on4 April 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note